

REMARKS

Prior to the present amendment, claims 67-102 were pending. In the amendment, claims 67, 69-71, 73-75, 77, 79, 83, 86-88, 93, 95, 97, 99, 101, and 102 are amended, claim 68 is cancelled, and new claims 103-108 are added.

Claim 67 has been amended to recite a cyclic imide residue. Support for this change is found, for example, at page 11, lines 24-25 of the specification. Support for the remaining changes to claim 67 is found, for example, in now-cancelled claim 68. Claim 70 has been amended to recite that the cyclic imide is an aspartimide or a glutamide. Support for this change is found, for example, at page 11, lines 26-28. Claim 75 is amended to correct typographic errors and to add the compound des Pro³⁶ [D-IsoAsp²⁸]Exendin-4(1-39). Support for this compound is found, for example, in Figure 9. Claims 77 and 83 has been amended to remove compounds, and to correct minor typographical and language issues. Claim 86 has been amended to recite the structure of a cyclic imide. Support for this change is found, for example, on page 30 of the specification. Claim 102 has been amended to recite the language of pending claim 101. New claims 103-108 recite stabilized exendin-4 compounds. Support for these changes is found, for example, on page 13-16 and 20-21 of the specification. Claims 69, 71, 73, 74, 79, 87-89, 93, 95, 97, 99, and 101 have been amended for proper claim dependencies and references in view of the other claim amendments. No new matter has been added by the present amendment.


If there are any additional charges or any credits, please apply them to Deposit

Account No. 03-2095.

Respectfully submitted,

Date:

February 12, 2008



Kristina Bieker-Brady, Ph.D.

Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045